Teleflex (NYSE:TFX) Updates FY 2026 Earnings Guidance

Posted by Francis Steltz on Aug 7th, 2026

Teleflex (NYSE:TFX – Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 6.900-7.200 for the period, compared to the consensus earnings per share estimate of 6.700. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Wall Street Analyst Weigh In

A number of brokerages have commented on TFX. Truist Financial reaffirmed a “hold” rating and issued a $143.00 price target (up from $135.00) on shares of Teleflex in a research note on Monday, May 11th. Wells Fargo & Company lifted their target price on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. Needham & Company LLC raised their price target on shares of Teleflex from $147.00 to $159.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, BMO Capital Markets assumed coverage on shares of Teleflex in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $148.90.

Get Our Latest Stock Report on TFX

Teleflex Stock Down 0.1%

Shares of NYSE:TFX traded down $0.10 during trading on Friday, hitting $138.79. The stock had a trading volume of 47,449 shares, compared to its average volume of 795,698. The firm’s fifty day moving average is $131.61 and its 200 day moving average is $122.46. The company has a market capitalization of $6.14 billion, a PE ratio of -6.09, a PEG ratio of 1.02 and a beta of 0.81. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. Teleflex has a 12 month low of $100.18 and a 12 month high of $145.00.

Teleflex (NYSE:TFX – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The business had revenue of $570.33 million for the quarter, compared to analysts’ expectations of $559.59 million. During the same quarter in the prior year, the company earned $3.73 earnings per share. The business’s revenue was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Analysts anticipate that Teleflex will post 6.7 EPS for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s dividend payout ratio is -5.96%.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

Positive Sentiment: Adjusted Q2 results exceeded expectations. Teleflex reported adjusted earnings of $1.76 per share, well above the $1.28 consensus estimate, while revenue reached $570.3 million versus expectations of $559.6 million. Revenue increased 28.9% year over year, or 4.7% on a pro forma, constant-currency basis. Teleflex Surpasses Q2 Earnings and Revenue Estimates
Positive Sentiment: Full-year profit guidance was raised or reaffirmed above analyst expectations. Teleflex forecast 2026 adjusted EPS of $6.90-$7.20, compared with the $6.70 analyst consensus. Revenue guidance of approximately $2.3 billion was broadly in line with expectations, suggesting earnings growth and execution are the primary positives. Teleflex Reports Second Quarter Results and 2026 Outlook
Positive Sentiment: The quarterly dividend supports shareholder returns. Teleflex declared a $0.34-per-share quarterly dividend, payable September 30 to shareholders of record August 14. The annualized payout is approximately $1.36 per share, representing a yield near 1%.
Neutral Sentiment: Recent coverage also highlights Teleflex’s FDA approval and a reported $1.5 billion original-equipment-manufacturer sale as potential strategic catalysts, though the near-term financial contribution and valuation impact remain uncertain. Teleflex FDA Approval and OEM Sale
Negative Sentiment: GAAP profitability weakened. GAAP diluted EPS from continuing operations was $0.96, down from $1.54 a year earlier, while adjusted EPS also declined from $3.73. Teleflex’s reported negative net margin may temper enthusiasm despite the adjusted earnings beat.

Institutional Trading of Teleflex

A number of large investors have recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its holdings in shares of Teleflex by 57.1% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 113 shares during the period. Kestra Advisory Services LLC bought a new stake in Teleflex during the 4th quarter valued at about $45,000. Danske Bank A S purchased a new stake in shares of Teleflex in the third quarter valued at approximately $54,000. State of Wyoming purchased a new position in shares of Teleflex during the second quarter valued at $111,000. Finally, EverSource Wealth Advisors LLC increased its position in Teleflex by 108.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock valued at $119,000 after purchasing an additional 521 shares during the period. Institutional investors own 95.62% of the company’s stock.

About Teleflex

(Get Free Report)

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.